MBRX
NASDAQMoleculin Biotech Inc.
News · 26 weeks65+143%
2026-03-012026-08-23
Mix3590d
- SEC Filings17(49%)
- Other10(29%)
- Insider6(17%)
- Offering1(3%)
- Dividends1(3%)
Latest news
25 items- SECSEC Form SCHEDULE 13D filed by Moleculin Biotech Inc.SCHEDULE 13D - Moleculin Biotech, Inc. (0001659617) (Subject)
- SECSEC Form SCHEDULE 13D filed by Moleculin Biotech Inc.SCHEDULE 13D - Moleculin Biotech, Inc. (0001659617) (Subject)
- SECSEC Form DEFA14A filed by Moleculin Biotech Inc.DEFA14A - Moleculin Biotech, Inc. (0001659617) (Filer)
- SECSEC Form DEF 14A filed by Moleculin Biotech Inc.DEF 14A - Moleculin Biotech, Inc. (0001659617) (Filer)
- SECSEC Form 424B5 filed by Moleculin Biotech Inc.424B5 - Moleculin Biotech, Inc. (0001659617) (Filer)
- SECSEC Form PRE 14A filed by Moleculin Biotech Inc.PRE 14A - Moleculin Biotech, Inc. (0001659617) (Filer)
- SECMoleculin Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Moleculin Biotech, Inc. (0001659617) (Filer)
- PRMoleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE TrialPositive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AMLMIRACLE trial advancing toward planned 90-patient enrollment milestone in September 2026 with the unblinded efficacy readout in December 2026 to February 2027 timeframeMIRACLE trial Part B initiation expected in the first half of 2027 following optimal dose selectionCash position, including $9.3 million raised after quarter-end, expected to fund operations into the first quarter of 2027Absence of cardiotoxicity continues in the MIRACLE trial HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today reported fi
- SECSEC Form 10-Q filed by Moleculin Biotech Inc.10-Q - Moleculin Biotech, Inc. (0001659617) (Filer)
- SECSEC Form SCHEDULE 13G filed by Moleculin Biotech Inc.SCHEDULE 13G - Moleculin Biotech, Inc. (0001659617) (Subject)
- SECSEC Form SCHEDULE 13G filed by Moleculin Biotech Inc.SCHEDULE 13G - Moleculin Biotech, Inc. (0001659617) (Subject)
- INSIDERCEO and President Klemp Walter V bought 533,333 shares, increasing direct ownership by 1,720% to 564,340 units (SEC Form 4)4 - Moleculin Biotech, Inc. (0001659617) (Issuer)
- INSIDERChief Financial Officer Foster Jonathan P. bought 293,333 shares, increasing direct ownership by 2,377% to 305,673 units (SEC Form 4)4 - Moleculin Biotech, Inc. (0001659617) (Issuer)
- INSIDERChief Science Officer Picker Donald H bought 173,333 shares, increasing direct ownership by 23,019% to 174,086 units (SEC Form 4)4 - Moleculin Biotech, Inc. (0001659617) (Issuer)
- SECMoleculin Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Moleculin Biotech, Inc. (0001659617) (Filer)
- SECSEC Form 424B5 filed by Moleculin Biotech Inc.424B5 - Moleculin Biotech, Inc. (0001659617) (Filer)
- SECSEC Form EFFECT filed by Moleculin Biotech Inc.EFFECT - Moleculin Biotech, Inc. (0001659617) (Filer)
- PRMoleculin Announces Pricing of $9.3 Million Public OfferingHOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced the pricing of a best-efforts public offering of an aggregate of 12,376,667 shares of common stock (or pre-funded warrants in lieu thereof), and warrants (the "Common Warrants") to purchase up to 37,130,001 shares of common stock at a combined public offering price of $0.75 per share of common stock (or pre-funded warrant in lieu thereof) and associated warrants. The Common Warrants will be immediately exercisable at an exercise price of $0.75 per share and will expire five years following the initial exercise date. The offering is expected to close on or about
- PRMoleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed PatientsPrior venetoclax failure — a setting in which published salvage remission rates are approximately 13% and median survival approximately 2.4 months — shows no adverse impact on blinded composite remission rates as MIRACLE approaches the end of Part A Preliminary blinded CR of 24% and CRc of 37% (n=62), with essentially identical rates among the 30 patients who had failed first-line venetoclax: CR of 23% and CRc of 37% (3X the published salvage remission rates following first-line venetoclax failure of approximately 13%)Enrollment reaches 74 of 90 patients, with final Part A treatment expected in September 2026 and comprehensive unblinded Part A results on track for the planned December 2026–
- SECMoleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Moleculin Biotech, Inc. (0001659617) (Filer)
- SECAmendment: SEC Form S-1/A filed by Moleculin Biotech Inc.S-1/A - Moleculin Biotech, Inc. (0001659617) (Filer)
- SECAmendment: SEC Form S-1/A filed by Moleculin Biotech Inc.S-1/A - Moleculin Biotech, Inc. (0001659617) (Filer)
- SECSEC Form S-1 filed by Moleculin Biotech Inc.S-1 - Moleculin Biotech, Inc. (0001659617) (Filer)
- PRMoleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" SegmentAccess the segment here HOUSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor "What This Means" segment. For the segment, Chairman and CEO Wally Klemp discusses the positive preliminary unblinded efficacy results from the first 45 patients enrolled in Part A of the pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in relapsed or refractory acute myeloid leukemia (R/R AML). During the conversation, Mr. Klemp provides his perspective on the significance of the early efficacy trends observed across both Annamy
- SECMoleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Moleculin Biotech, Inc. (0001659617) (Filer)
MBRX FAQ
7 questionsWhat does Moleculin Biotech Inc. do?
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates for the treatment of highly resistant tumors and viruses in the United States. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and hematologic malignancies...Where does MBRX stock trade?
Moleculin Biotech Inc. (MBRX) is listed on NASDAQ.What sector and industry is MBRX in?
Moleculin Biotech Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Moleculin Biotech Inc. go public?
Moleculin Biotech Inc. (MBRX) completed its IPO in 2016.What are analysts saying about MBRX?
Moleculin Biotech Inc. has had 3 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $400.00 price target on 2025-06-09. Recent price targets range from $400.00 to $1400.00.What companies are similar to MBRX?
Notable peers in the same industry include KRYS (Krystal Biotech Inc.), BBI (Brickell Biotech Inc.), PMCB (PharmaCyte Biotech Inc.). Compare MBRX side-by-side with any of them on Quantisnow.How can I track MBRX on Quantisnow?
Quantisnow aggregates Moleculin Biotech Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MBRX to receive live email and push alerts on every new disclosure.